Orchard Therapeutics
OverviewSuggest Edit
Orchard Therapeutics is a biotechnology company, develops and commercializes transformative ex-vivo autologous hematopoietic stem cell gene therapy to restore normal gene function in primary immune deficiencies, metabolic diseases, and hematological disorders. The сompany also develops adenosine deaminase severe combined immunodeficiency, mucopolysaccharidosis type IIIA, and ex-vivo lentiviral gene therapy programs.
| Type | Public | |
| Founded | 2015 | |
| HQ | London, GB | Map |
| Website | orchard-tx.com | |
| Employee Ratings | More |
Recent NewsAll News
- Orchard Therapeutics Reports 2020 Financial Results and Reviews Recent Accomplishments
- Orchard Therapeutics to Present at Multiple Investor Conferences in March 2021
- Thinking about buying stock in Novan, Baudax Bio, Tyme Technologies, Orchard Therapeutics, or electroCore?
- Orchard Therapeutics Announces Interim Data for OTL-203 Showing Positive Clinical Results in Multiple Disease Manifestations of Mucopolysaccharidosis Type I Hurler Syndrome (MPS-IH)
Key People/Management at Orchard Therapeutics
Bobby Gaspar
Chief Executive Officer, Director
John Cerio
Chief Human Resource Officer
Adrien Lemoine
Chief Business Officer
Anne Dupraz-Poiseau
Chief Development Officer
John Ilett
Chief of Staff, Chief Legal Officer & Company Secretary
Frank Thomas
President & Chief Operating Officer
Orchard Therapeutics Office Locations
Orchard Therapeutics has offices in London, Boston, Foster City and Menlo Park
London, GB (HQ)
108 Cannon St
Boston, MA, US
101 Seaport Blvd 7th floor
Boston, MA, US
2 Seaport Ln 8th floor
Foster City, CA, US
1118 Chess Dr
Menlo Park, CA, US
1360 O'Brien Dr
Orchard Therapeutics Financials and Metrics
Orchard Therapeutics Revenue
Orchard Therapeutics's revenue was reported to be £1.66 m in FY, 2018
| GBP | |
|---|---|
Revenue (FY, 2018) | 1.7m |
Gross profit (FY, 2018) | 1.3m |
Gross profit margin (FY, 2018), % | 79.7% |
Net income (FY, 2018) | (184.4m) |
EBIT (FY, 2018) | (188.0m) |
Market capitalization (19-Apr-2021) | 731.0m |
Closing stock price (19-Apr-2021) | 5.9 |
Cash (31-Dec-2018) | 268.7m |
EV | 462.4m |
Orchard Therapeutics's current market capitalization is $731 m.
| GBP | FY, 2018 |
|---|---|
Revenue | 1.7m |
Cost of goods sold | 337.6k |
Gross profit | 1.3m |
Gross profit Margin, % | 80% |
| GBP | FY, 2017 | FY, 2018 |
|---|---|---|
Cash | 71.9m | 268.7m |
Accounts Receivable | 997.6k | 1.7m |
Current Assets | 75.4m | 284.4m |
| GBP | FY, 2017 | FY, 2018 |
|---|---|---|
Cash From Operating Activities | (26.0m) | (78.0m) |
Cash From Investing Activities | (1.2m) | (3.2m) |
Cash From Financing Activities | 92.6m | 283.9m |
Net Change in Cash | 65.3m | 202.6m |
| GBP | FY, 2017 |
|---|---|
Financial Leverage | 1.1 x |
Orchard Therapeutics Cybersecurity Score
Orchard Therapeutics Online and Social Media Presence
1.31k Twitter followers
Orchard Therapeutics has 1.31k Twitter Followers. The number of followers has increased 4.3% month over month and increased 15.6% quarter over quarter
Orchard Therapeutics's Trends
Twitter Engagement Stats for @orchard_tx
276
Tweets
431
Following
1.3k
Followers
6
Tweets last 30 days
2.8
Avg. likes per Tweet
100%
Tweets with engagement
Orchard Therapeutics News and Updates
March 02, 2021
Orchard Therapeutics Reports 2020 Financial Results and Reviews Recent Accomplishments
$150M Strategic Financing Supports Execution into the First Half of 2023
February 25, 2021
Orchard Therapeutics to Present at Multiple Investor Conferences in March 2021
BOSTON and LONDON, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that members of the management team will present at the following virtual investor conferences:
February 09, 2021
Thinking about buying stock in Novan, Baudax Bio, Tyme Technologies, Orchard Therapeutics, or electroCore?
NEW YORK, Feb. 9, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NOVN, BXRX, TYME, ORTX, and ECOR. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
February 09, 2021
Orchard Therapeutics Announces Interim Data for OTL-203 Showing Positive Clinical Results in Multiple Disease Manifestations of Mucopolysaccharidosis Type I Hurler Syndrome (MPS-IH)
All eight patients treated with OTL-203 show stable cognitive function, motor function and growth within the normal range at multiple data points post-treatment
February 05, 2021
Thinking about buying stock in LAIX Inc, Inuvo Inc, GameStop, Orchard Therapeutics, or AMC Entertainment?
NEW YORK, Feb. 5, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LAIX, INUV, GME, ORTX, and AMC. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
February 05, 2021
Orchard Therapeutics Announces $150 Million Strategic Financing
Strengthened Financial Position Supports Execution into the First Half of 2023 Strengthened Financial Position Supports Execution into the First Half of 2023
Orchard Therapeutics Blogs
March 03, 2021
Be The Match BioTherapies® Announces Expansion of Multi-Year Strategic Alliance with Orchard Therapeutics to Support European Commercial Launch of Libmeldy™
Be The Match BioTherapies® Announces Expansion of Multi-Year Strategic Alliance with Orchard Therapeutics to Support European Commercial Launch of Libmeldy™
Content Import
Wed, 03/03/2021 - 09:01
Be The Match BioTherapies® Announces Expansion of Multi-Year Strategic Alliance with Orchard T…
February 24, 2021
Patient Engagement in the Era of Gene Therapy
The post Patient Engagement in the Era of Gene Therapy appeared first on Orchard Therapeutics.
January 19, 2021
Orchard Therapeutics Secures Partnerships to Broaden Access to Libmeldy™ for Eligible Patients in Middle East & Turkey
BOSTON and LONDON, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced plans to extend the company’s commercial reach in the Middle East and Turkey through exclusive agreements with GenPharm Services and GEN, two leading regional
January 14, 2021
Orchard Therapeutics Announces OTL-200 Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by FDA for the Treatment of Metachromatic Leukodystrophy (MLD)
Orchard Therapeutics Announces OTL-200 Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by FDA for the Treatment of Metachromatic Leukodystrophy (MLD)
Content Import
Thu, 01/14/2021 - 07:00
Orchard Therapeutics Announces OTL-200 Granted Regenerative Medicine Advanced Thera…
January 11, 2021
Emma Nealon
Emma Nealon
Jonathan.Lorin…
Mon, 01/11/2021 - 15:07
Emma
Nealon
Cantor Fitzgerald
December 24, 2020
Reflecting on the Past Year, Looking Toward New Horizons
The post Reflecting on the Past Year, Looking Toward New Horizons appeared first on Orchard Therapeutics.
Orchard Therapeutics Frequently Asked Questions
When was Orchard Therapeutics founded?
Orchard Therapeutics was founded in 2015.
Who are Orchard Therapeutics key executives?
Orchard Therapeutics's key executives are Bobby Gaspar, John Cerio and Adrien Lemoine.
How many employees does Orchard Therapeutics have?
Orchard Therapeutics has 252 employees.
What is Orchard Therapeutics revenue?
Latest Orchard Therapeutics annual revenue is £1.7 m.
What is Orchard Therapeutics revenue per employee?
Latest Orchard Therapeutics revenue per employee is £6.6 k.
Who are Orchard Therapeutics competitors?
Competitors of Orchard Therapeutics include Affinia Therapeutics, AID Genomics and Annexon Biosciences.
Where is Orchard Therapeutics headquarters?
Orchard Therapeutics headquarters is located at 108 Cannon St, London.
Where are Orchard Therapeutics offices?
Orchard Therapeutics has offices in London, Boston, Foster City and Menlo Park.
How many offices does Orchard Therapeutics have?
Orchard Therapeutics has 5 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies